PriceTargets.com logo

Opus Genetics - IRD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.77
  • Forecasted Upside: 190.28%
  • Number of Analysts: 18
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 15 Buy Ratings
  • 1 Strong Buy Ratings
$3.71 As of 07/31/2026 05:00 PM ET
▼ -0.13 (-3.39%)

This chart shows the closing price for IRD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Opus Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRD

Analyst Price Target is $10.77
▲ +190.28% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Opus Genetics in the last 3 months. The average price target is $10.77, with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 190.28% upside from the last price of $3.71.

This chart shows the closing price for IRD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 18 contributing investment analysts is to moderate buy stock in Opus Genetics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 2 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/2/2026
  • 1 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
8/1/2026

Latest Recommendations

  • 1 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2026TD CowenInitiated CoverageBuy
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/13/2026Zacks ResearchDowngradeHold ➝ Strong Sell
7/6/2026Chardan CapitalReiterated RatingBuy ➝ Buy$13.00
7/6/2026BTIG ResearchReiterated RatingBuy ➝ Buy$12.00
6/23/2026Royal Bank Of CanadaInitiated CoverageOutperform$10.00
6/23/2026Royal Bank Of CanadaInitiated CoverageModerate Buy$10.00
6/18/2026Chardan CapitalBoost TargetBuy ➝ Buy$11.00 ➝ $13.00
6/17/2026Chardan CapitalUpgradeStrong-Buy
6/17/2026HC WainwrightReiterated RatingBuy ➝ Buy$8.00
6/16/2026BTIG ResearchReiterated RatingBuy ➝ Buy$12.00
6/15/2026Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$11.00
6/10/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
6/4/2026GuggenheimInitiated CoverageBuy$16.00
6/4/2026GuggenheimInitiated CoverageBuy$16.00
5/21/2026Leerink PartnersInitiated CoverageOutperform$10.00
5/13/2026Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $11.00
5/12/2026Zacks ResearchDowngradeHold ➝ Strong Sell
4/30/2026B. Riley FinancialReiterated RatingBuy ➝ Buy
4/28/2026CitigroupInitiated CoverageOutperform
4/28/2026Citizens JmpInitiated CoverageMarket Perform$12.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/30/2026Cantor FitzgeraldInitiated CoverageOverweight$15.00
3/16/2026OppenheimerInitiated CoverageOutperform$10.00
3/12/2026Chardan CapitalBoost TargetBuy ➝ Buy$9.00 ➝ $11.00
3/12/2026WedbushBoost TargetOutperform ➝ Outperform$8.00 ➝ $10.00
3/11/2026Craig HallumSet TargetBuy ➝ Buy$9.00
3/2/2026BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $12.00
2/12/2026Lifesci CapitalUpgradeStrong-Buy
1/28/2026BTIG ResearchReiterated RatingBuy ➝ Buy$7.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/20/2026BTIG ResearchInitiated CoverageBuy$7.00
1/20/2026BTIG ResearchInitiated CoverageBuy$7.00
12/10/2025B. Riley FinancialInitiated CoverageBuy$9.00
11/25/2025Piper SandlerInitiated CoverageOverweight$7.00
11/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$9.00
11/7/2025Chardan CapitalReiterated RatingBuy ➝ Buy$9.00
10/29/2025WedbushInitiated CoverageOutperform$8.00
10/16/2025Chardan CapitalInitiated CoverageBuy$9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00
4/11/2025Craig HallumInitiated CoverageBuy$6.00
4/1/2025JonesTradingLower TargetBuy ➝ Buy$9.00 ➝ $8.00
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
2/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
11/13/2024HC WainwrightInitiated CoverageBuy$8.00
(Data available from 8/1/2021 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026

Current Sentiment

  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Opus Genetics logo
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Read More

Today's Range

Now: $3.71
Low: $3.62
High: $3.86

50 Day Range

MA: $3.86
Low: $2.92
High: $4.64

52 Week Range

Now: $3.71
Low: $1.04
High: $5.81

Volume

970,360 shs

Average Volume

835,976 shs

Market Capitalization

$306.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Opus Genetics?

The following sell-side analysts have issued research reports on Opus Genetics in the last twelve months: B. Riley Financial, Inc., BTIG Research, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Citizens Jmp, Craig Hallum, Guggenheim, HC Wainwright, Leerink Partners, Lifesci Capital, Oppenheimer Holdings, Inc., Piper Sandler, Royal Bank Of Canada, TD Cowen, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for IRD.

What is the current price target for Opus Genetics?

0 Wall Street analysts have set twelve-month price targets for Opus Genetics in the last year. Their average twelve-month price target is $10.77, suggesting a possible upside of 190.3%. Guggenheim has the highest price target set, predicting IRD will reach $16.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Opus Genetics in the next year.
View the latest price targets for IRD.

What is the current consensus analyst rating for Opus Genetics?

Opus Genetics currently has 2 sell ratings, 15 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IRD.

What other companies compete with Opus Genetics?

Other companies that are similar to Opus Genetics include Corvus Pharmaceuticals, Cullinan Therapeutics, Cronos Group, Forte Biosciences and Vor Biopharma. Learn More about companies similar to Opus Genetics.

How do I contact Opus Genetics' investor relations team?

Opus Genetics' physical mailing address is 37000 GRAND RIVER AVE. SUITE 120, FARMINGTON HILLS MI, 48335. The company's listed phone number is 248-957-9024 and its investor relations email address is [email protected]. The official website for Opus Genetics is www.ocuphire.com. Learn More about contacing Opus Genetics investor relations.